Lupin Expands US Inhalation Business With Two Sunovion Brands
Indian Firm Pays $75m For US Rights To Respiratory Brands Brovana And Xopenex HFA
Executive Summary
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
You may also be interested in...
Lupin Launch In Germany Supports Respiratory Push
Lupin has revealed details of the German launch of its Luforbec (beclometasone/formoterol) branded generic rival to Foster through its local Hormosan subsidiary, as part of the Indian firm’s wider push in the respiratory category.
Lupin Delivers On US Generic Spiriva Approval
Lupin has gained a long-awaited FDA approval for its US generic version of Spiriva. The product is seen as a major element of Lupin’s respiratory franchise and a key contributor to the Indian firm’s fortunes this year.
Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.